Unlocking
the future
of medicine

About us

Offering an unrivalled modular platform and tailored hyper-targeting is how we stand apart

Pipeline

Reducing the impact of cancer and autoimmune diseases on people’s lives is why we’re here

Research and development

Pushing the boundaries of human advancement in medicine is what drives us every day

Investors
 
 
 

An immunotherapy platform that unlocks unlimited possibilities for the future of medicine

The Nykode Therapeutics platform is built around the Vaccibody molecule. Inducing fast, strong and long-lasting immune responses, and demonstrating a positive safety profile, our pioneering Vaccibody™ immunotherapy has the potential to treat many disease areas, including cancer.

Highlights

Nykode Therapeutics – Annual Report 2024

Read More
29 April 2025

Nykode Therapeutics – Key information relating to proposed cash ...

Read More
28 April 2025

Nykode Announces that Michael Engsig, CEO; Agnete Fredriksen, CSO ...

Read More
15 April 2025

Nykode Therapeutics ASA – Notice of Extraordinary General Meeting

Read More
02 April 2025

Nykode Therapeutics – resignation of Chair of the Board, ...

Read More
27 March 2025

Nykode Therapeutics Announces Preclinical Data Highlighting its Immune Tolerance ...

Read More
27 February 2025

Nykode Therapeutics reports Q4 2024 Financial Results

Read More
26 February 2025

Nykode Therapeutics – invitation to Q4 2024 financial results ...

Read More
14 February 2025

Nykode Therapeutics Announces Publication of Phase 2 VB-C-02 Data ...

Read More
08 January 2025